CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Despite remarkable success in the treatment of hematological malignancies, CAR T-cell therapies for solid tumors have floundered, in large part due to local immune suppression and the effects of prolonged stimulation leading to T-cell dysfunction and exhaustion. One mechanism by which gliomas and ot...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Immunother Cancer
Главные авторы: Choi, Bryan D., Yu, Xiaoling, Castano, Ana P., Darr, Henia, Henderson, Daniel B., Bouffard, Amanda A., Larson, Rebecca C., Scarfò, Irene, Bailey, Stefanie R., Gerhard, Genevieve M., Frigault, Matthew J., Leick, Mark B., Schmidts, Andrea, Sagert, Jason G., Curry, William T., Carter, Bob S., Maus, Marcela V.
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2019
Предметы:
Short Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6857271/
https://ncbi.nlm.nih.gov/pubmed/31727131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0806-7
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы